|
US2017189397A1
|
|
Headache pre-emption by dihydroergotamine treatment during headache precursor events
|
|
US2015023888A1
|
|
Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine
|
|
US2014377365A1
|
|
Sustained-release formulation of rotigotine
|
|
US2014377189A1
|
|
Pulmonary administration of rotigotine
|
|
AU2014202153A1
|
|
Dose counter and lockout mechanism
|
|
CA2895829A1
|
|
Novel methysergide derivatives
|
|
AU2013361343A1
|
|
Fluoroergoline derivatives and uses thereof
|
|
CA2895834A1
|
|
Novel ergoline derivatives and uses thereof
|
|
US2014179705A1
|
|
8'-hydroxy-dihydroergotamine compounds and compositions
|
|
AU2013361337A1
|
|
8'-Hydroxy-Dihydroergotamine compounds and compositions
|
|
WO2013096560A1
|
|
Excipient-free aerosol formulation
|
|
SG11201403433PA
|
|
Novel neuromodulatory compounds
|
|
CN104822264A
|
|
Novel cabergoline derivatives
|
|
KR20140042868A
|
|
Novel fluoroergoline analogs
|
|
EP2793580A1
|
|
Novel iso-ergoline derivatives
|
|
AU2011239367A1
|
|
Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
|
|
AU2011305567A1
|
|
Corticosteroid particles and method of production
|
|
EP2515978A1
|
|
Enhanced eductor design
|
|
WO2011079313A1
|
|
Novel ergoline analogs
|
|
WO2010151804A1
|
|
Administration of dihydroergotamine mesylate particles using a metered dose inhaler
|
